Entest Group Inc

[ronrooster]

ENTB and RGBP potential comparison re NR2F6.
The two companies are set up totally opposite in relationship to Revenue recognition.
Any revenue generated by Zander will flow up 100% to ENTB since Zander is 100% ENTB subsidiary.
Revenue generated by RGBP ( only through Checkpoint Immunology ) will only generate a established percentage for RGBP (i.e. 8% for revenue under 1 Billion).
Granted RGBP owns 20% of ENTB o/s shares, however the following example clearly demonstrates why ENTB's potential is dramatically superior to RGBP but mainly most other biotechs.
Assuming; Checkpoint negotiates 500 m deal, this would yield RGBP only 40 m revenue.The o/s total ( common and preferred) total over 293 million.
If Zander negotiates a mere 50 m deal, the total 50 million would flow up to ENTB. (o/s 40m).
Anyway the above is result of an quiet sunday morning.GLTA